Antares Pharma Stock Price and Value Analysis

Should you buy Antares Pharma stock? (NasdaqCM:ATRS). Let's see how it does in our automated value investing analysis system.

ATRS Free Cash Flow Trend

Free Cash Flow trendline for ATRS
Free Cash Flow trendline for Antares Pharma

Hmm, we can't give any reliable projection for Antares Pharma's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ATRS Numbers

ATRS Price
(Antares Pharma stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Medical Instruments & Supplies stocks
[?] Cash Yield -0.41%
[?] Free Cash Flow Jitter 47%

Is Antares Pharma Stock on Sale?

Based on our analysis, we believe that you should not buy Antares Pharma right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy ATRS Stock?

Does Antares Pharma have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.